Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C

BMC Cancer

Kyu Kwang Kim³  Thilo S Lange²  Rakesh K Singh³  Laurent Brard¹  Richard G Moore³ 

[1] Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Southern Illinois University School of Medicine, Springfield, IL 62794, USA

[2] Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, RI 02912, USA

[3] Molecular Therapeutics Laboratory, Program in Women's Oncology, Departments of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, 101 Dudley Street, Providence, RI 02905, USA

关键词: ROS generation;    5-fluorouracil;    Fenretinide;    Mitomycin C;    Doxorubicin;    Combination treatment;    Tetrathiomolybdate;   

Others  :  1080460
DOI  :  10.1186/1471-2407-12-147

 received in 2011-12-07, accepted in 2012-04-13,  发布年份 2012

【 摘 要 】

Background

Our recent study showed that tetrathiomolybdate (TM), a drug to treat copper overload disorders, can sensitize drug-resistant endometrial cancer cells to reactive oxygen species (ROS)-generating anticancer drug doxorubicin. To expand these findings in the present study we explore TM efficacy in combination with a spectrum of ROS-generating anticancer drugs including mitomycin C, fenretinide, 5-fluorouracil and doxorubicin in ovarian cancer cells as a model system.

Methods

The effects of TM alone or in combination with doxorubicin, mitomycin C, fenretinide, or 5-fluorouracil were evaluated using a sulforhodamine B assay. Flow cytometry was used to detect the induction of apoptosis and ROS generation. Immunoblot analysis was carried out to investigate changes in signaling pathways.

Results

TM potentiated doxorubicin-induced cytotoxicity and modulated key regulators of apoptosis (PARP, caspases, JNK and p38 MAPK) in SKOV-3 and A2780 ovarian cancer cell lines. These effects were linked to the increased production of ROS, as shown in SKOV-3 cells. ROS scavenging by ascorbic acid blocked the sensitization of cells by TM. TM also sensitized SKOV-3 to mitomycin C, fenretinide, and 5-fluorouracil. The increased cytotoxicity of these drugs in combination with TM was correlated with the activity of ROS, loss of a pro-survival factor (e.g. XIAP) and the appearance of a pro-apoptotic marker (e.g. PARP cleavage).

Conclusions

Our data show that TM increases the efficacy of various anticancer drugs in ovarian cancer cells in a ROS-dependent manner.

【 授权许可】

   
2012 Kim et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]American Cancer Society: Cancer Facts and Figures. [http://www.cancer.org] webcite 2010.
• [2]Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial Lancet 2002, 360:505-515.
• [3]Bratasz A, Weir NM, Parinandi NL, Zweier JL, Sridhar R, Ignarro LJ, Kuppusamy P: Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin. Proc Natl Acad Sci USA 2006, 103:3914-3919.
• [4]McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1-6.
• [5]Medici V, Sturniolo GC: Tetrathiomolybdate, a copper chelator for the treatment of Wilson disease, pulmonary fibrosis and other indications. IDrugs 2008, 11:592-606.
• [6]Juarez JC, Betancourt O Jr, Pirie-Shepherd SR, Guan X, Price ML, Shaw DE, Mazar AP, Donate F: Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res 2006, 12:4974-4982.
• [7]Kim KK, Kawar NM, Singh RK, Lange TS, Brard L, Moore RG: Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines. Gynecol Oncol 2011, 122:183-189.
• [8]Koto KS, Lescault P, Brard L, Kim K, Singh RK, Bond J, Illenye S, Slavik MA, Ashikaga T, Saulnier Sholler GL: Antitumor activity of nifurtimox is enhanced with tetrathiomolybdate in medulloblastoma. Int J Oncol 2011, 38:1329-1341.
• [9]Ishida S, McCormick F, Smith-McCune K, Hanahan D: Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 2010, 17:574-583.
• [10]Kumar P, Yadav A, Patel SN, Islam M, Pan Q, Merajver SD, Teknos TN: Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis. Mol Cancer 2010, 9:206. BioMed Central Full Text
• [11]Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K, Redman BG, Jahan T, Sondak VK, et al.: Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res 2000, 6:1-10.
• [12]Pass HI, Brewer GJ, Dick R, Carbone M, Merajver S: A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann Thorac Surg 2008, 86:383-389.
• [13]Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, Brewer GJ, Merajver SD: Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 2003, 9:1666-1672.
• [14]Creech RH, Shah MK, Catalano RB, Dierks K, Dayal H, Goldberg-Alberts R: Phase II study of low-dose mitomycin in patients with ovarian cancer previously treated with chemotherapy. Cancer Treat Rep 1985, 69:1271-1273.
• [15]Rosa DD, Awada A, Mano MS, Selleslags J, Lebrun F, Gil T, Piccart MJ, D'Hondt V: Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma. Arch Gynecol Obstet 2008, 278:457-462.
• [16]Weiss RB: The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992, 19:670-686.
• [17]Garcia AA, Morgan R, McNamara M, Scudder S, Tsao-Wei D, Groshen S, Frgala T, Kim Y, Reynolds CP: Phase II trial of fenretinide (4-HPR) in recurrent ovarian and primary peritoneal carcinoma: A California Cancer Consortium trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004, 22:5056.
• [18]Appierto V, Tiberio P, Villani MG, Cavadini E, Formelli F: PLAB induction in fenretinide-induced apoptosis of ovarian cancer cells occurs via a ROS-dependent mechanism involving ER stress and JNK activation. Carcinogenesis 2009, 30:824-831.
• [19]Koedrith P, Seo YR: Enhancement of the efficacy of mitomycin c-mediated apoptosis in human colon cancer cells with RNAi-based thioredoxin reductase 1 deficiency. Experimental and Therapeutic Medicine 2011, 2:873-878.
• [20]Hwang PM, Bunz F, Yu J, Rago C, Chan TA, Murphy MP, Kelso GF, Smith RA, Kinzler KW, Vogelstein B: Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat Med 2001, 7:1111-1117.
• [21]Sinha BK, Mimnaugh EG, Rajagopalan S, Myers CE: Adriamycin activation and oxygen free radical formation in human breast tumor cells: protective role of glutathione peroxidase in adriamycin resistance. Cancer Res 1989, 49:3844-3848.
• [22]Vichai V, Kirtikara K: Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006, 1:1112-1116.
• [23]Kim KK, Singh RK, Strongin RM, Moore RG, Brard L, Lange TS: Organometallic Iron(III)-Salophene Exerts Cytotoxic Properties in Neuroblastoma Cells via MAPK Activation and ROS Generation. PLoS One 2011, 6:e19049.
• [24]Kim R, Emi M, Tanabe K, Murakami S, Uchida Y, Arihiro K: Regulation and interplay of apoptotic and non-apoptotic cell death. J Pathol 2006, 208:319-326.
• [25]Petit PX, Lecoeur H, Zorn E, Dauguet C, Mignotte B, Gougeon ML: Alterations in mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis. J Cell Biol 1995, 130:157-167.
• [26]Gewirtz DA: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999, 57:727-741.
• [27]Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM: Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res 2006, 66:4863-4871.
• [28]Dusre L, Mimnaugh EG, Myers CE, Sinha BK: Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells. Cancer Res 1989, 49:511-515.
• [29]Gouaze V, Mirault ME, Carpentier S, Salvayre R, Levade T, Andrieu-Abadie N: Glutathione peroxidase-1 overexpression prevents ceramide production and partially inhibits apoptosis in doxorubicin-treated human breast carcinoma cells. Mol Pharmacol 2001, 60:488-496.
• [30]Li S, Zhou Y, Wang R, Zhang H, Dong Y, Ip C: Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates. Mol Cancer Ther 2007, 6:1031-1038.
• [31]Hou G, Dick R, Abrams GD, Brewer GJ: Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice. J Lab Clin Med 2005, 146:299-303.
• [32]Shiraha Y, Sakai K, Teranaka T: Clinical trials of mitomycin C, a new antitumor antibiotic; preliminary report of results obtained in 82 consecutive cases in the field of general surgery. Antibiot Annu 1958, 6:533-540.
• [33]Aoki Y, Kurata H, Watanabe M, Fujita K, Tanaka K: Combination chemotherapy with irinotecan hydrochloride (CPT-11) and mitomycin C in platinum-refractory ovarian cancer. Am J Clin Oncol 2004, 27:461-464.
• [34]Brewer GJ, Johnson V, Dick RD, Kluin KJ, Fink JK, Brunberg JA: Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 1996, 53:1017-1025.
• [35]Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003, 3:330-338.
• [36]Prefontaine M, Donovan JT, Powell JL, Buley L: Treatment of refractory ovarian cancer with 5-fluorouracil and leucovorin. Gynecol Oncol 1996, 61:249-252.
• [37]Wu JM, DiPietrantonio AM, Hsieh TC: Mechanism of fenretinide (4-HPR)-induced cell death. Apoptosis 2001, 6:377-388.
• [38]Gupte A, Mumper RJ: Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev 2009, 35:32-46.
• [39]Waris G, Ahsan H: Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog 2006, 5:14. BioMed Central Full Text
• [40]Hileman EO, Liu J, Albitar M, Keating MJ, Huang P: Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol 2004, 53:209-219.
• [41]Trachootham D, Alexandre J, Huang P: Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009, 8:579-591.
• [42]Kim JS, Lee JH, Jeong WW, Choi DH, Cha HJ, Kim DH, Kwon JK, Park SE, Park JH, Cho HR, et al.: Reactive oxygen species-dependent EndoG release mediates cisplatin-induced caspase-independent apoptosis in human head and neck squamous carcinoma cells. Int J Cancer 2008, 122:672-680.
• [43]Mansat-de Mas V, Bezombes C, Quillet-Mary A, Bettaieb A, D'orgeix AD, Laurent G, Jaffrezou JP: Implication of radical oxygen species in ceramide generation, c-Jun N-terminal kinase activation and apoptosis induced by daunorubicin. Mol Pharmacol 1999, 56:867-874.
• [44]Tsai-Turton M, Luong BT, Tan Y, Luderer U: Cyclophosphamide-induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion. Toxicol Sci 2007, 98:216-230.
• [45]Brown DP, Chin-Sinex H, Nie B, Mendonca MS, Wang M: Targeting superoxide dismutase 1 to overcome cisplatin resistance in human ovarian cancer. Cancer Chemother Pharmacol 2009, 63:723-730.
• [46]Kang YH, Lee SJ: The role of p38 MAPK and JNK in Arsenic trioxide-induced mitochondrial cell death in human cervical cancer cells. J Cell Physiol 2008, 217:23-33.
• [47]Osone S, Hosoi H, Kuwahara Y, Matsumoto Y, Iehara T, Sugimoto T: Fenretinide induces sustained-activation of JNK/p38 MAPK and apoptosis in a reactive oxygen species-dependent manner in neuroblastoma cells. Int J Cancer 2004, 112:219-224.
• [48]Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB, Claret FX: Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 2003, 278:19245-19256.